questionsmedicales.fr
Phénomènes génétiques
Phénotype
Sérogroupe
Sérogroupe : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Test ELISA
Immunofluorescence
Culture bactérienne
Identification des microorganismes
PCR
Détection des agents pathogènes
Historique médical
Évaluation clinique
Symptômes
5
Variabilité des symptômes
Sérogroupe
Complications
Gravité des symptômes
Évolution des symptômes
Traitement
Prévention
5
Prévention des infections
Hygiène
Efficacité des vaccins
Prévention
Hygiène
Prévention des infections
Voyages
Exposition aux infections
Comportements à risque
Prévention
Traitements
5
Traitement spécifique
Sérogroupe
Vaccins
Prévention des infections
Suivi médical
Efficacité du traitement
Médecine complémentaire
Traitements alternatifs
Complications
5
Septicémie
Complications infectieuses
Prévention des complications
Traitement précoce
Complications graves
Mortalité
Signes d'alerte
Complications
Facteurs de risque
5
Facteurs de risque
Immunodépression
Antécédents médicaux
Risque d'infection
Mode de vie
Prévention des infections
Voyages
Exposition aux infections
Conditions environnementales
Risque d'infection
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Sérogroupe : Questions médicales les plus fréquentes",
"headline": "Sérogroupe : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Sérogroupe : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-30",
"dateModified": "2025-04-26",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Sérogroupe"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Phénotype",
"url": "https://questionsmedicales.fr/mesh/D010641",
"about": {
"@type": "MedicalCondition",
"name": "Phénotype",
"code": {
"@type": "MedicalCode",
"code": "D010641",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G05.695"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Sérogroupe",
"alternateName": "Serogroup",
"code": {
"@type": "MedicalCode",
"code": "D065288",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Ray Borrow",
"url": "https://questionsmedicales.fr/author/Ray%20Borrow",
"affiliation": {
"@type": "Organization",
"name": "Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom."
}
},
{
"@type": "Person",
"name": "Bo Pang",
"url": "https://questionsmedicales.fr/author/Bo%20Pang",
"affiliation": {
"@type": "Organization",
"name": "State Key Laboratory for Infectious Disease Prevention and Control, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China. pangbo@icdc.cn."
}
},
{
"@type": "Person",
"name": "Biao Kan",
"url": "https://questionsmedicales.fr/author/Biao%20Kan",
"affiliation": {
"@type": "Organization",
"name": "State Key Laboratory for Infectious Disease Prevention and Control, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China. kanbiao@icdc.cn."
}
},
{
"@type": "Person",
"name": "Lucy A McNamara",
"url": "https://questionsmedicales.fr/author/Lucy%20A%20McNamara",
"affiliation": {
"@type": "Organization",
"name": "Meningitis and Vaccine Preventable Diseases Branch, Centers for Disease Control and Prevention, Atlanta, USA."
}
},
{
"@type": "Person",
"name": "None None",
"url": "https://questionsmedicales.fr/author/None%20None",
"affiliation": {
"@type": "Organization",
"name": ""
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Amphetamine-like Deferiprone and Clioquinol Derivatives as Iron Chelating Agents.",
"datePublished": "2024-09-05",
"url": "https://questionsmedicales.fr/article/39275060",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/molecules29174213"
}
},
{
"@type": "ScholarlyArticle",
"name": "A novel C19ORF12 mutation in two MPAN sisters treated with deferiprone.",
"datePublished": "2023-03-31",
"url": "https://questionsmedicales.fr/article/37004026",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12883-023-03172-z"
}
},
{
"@type": "ScholarlyArticle",
"name": "Deferiprone-gallium-protoporphyrin (IX): A promising treatment modality against Mycobacterium abscessus.",
"datePublished": "2023-07-24",
"url": "https://questionsmedicales.fr/article/37506532",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.tube.2023.102390"
}
},
{
"@type": "ScholarlyArticle",
"name": "No difference in myocardial iron concentration and serum ferritin with deferasirox and deferiprone in pediatric patients with hemoglobinopathies: A systematic review and meta-analysis.",
"datePublished": "2022-07-22",
"url": "https://questionsmedicales.fr/article/35878782",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.tracli.2022.07.004"
}
},
{
"@type": "ScholarlyArticle",
"name": "Deferiprone: A Forty-Year-Old Multi-Targeting Drug with Possible Activity against COVID-19 and Diseases of Similar Symptomatology.",
"datePublished": "2022-06-16",
"url": "https://questionsmedicales.fr/article/35743183",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijms23126735"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Phénomènes génétiques",
"item": "https://questionsmedicales.fr/mesh/D055614"
},
{
"@type": "ListItem",
"position": 3,
"name": "Phénotype",
"item": "https://questionsmedicales.fr/mesh/D010641"
},
{
"@type": "ListItem",
"position": 4,
"name": "Sérogroupe",
"item": "https://questionsmedicales.fr/mesh/D065288"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Sérogroupe - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Sérogroupe",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-14",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Sérogroupe",
"description": "Comment identifier un sérogroupe spécifique ?\nQuels tests sont utilisés pour le diagnostic ?\nPeut-on diagnostiquer par culture ?\nLes tests PCR sont-ils utiles ?\nQuel rôle joue l'historique médical ?",
"url": "https://questionsmedicales.fr/mesh/D065288?mesh_terms=Deferiprone#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Sérogroupe",
"description": "Quels symptômes sont associés aux infections par sérogroupe ?\nLes symptômes varient selon le sérogroupe ?\nY a-t-il des symptômes communs ?\nLes symptômes peuvent-ils être graves ?\nComment les symptômes évoluent-ils ?",
"url": "https://questionsmedicales.fr/mesh/D065288?mesh_terms=Deferiprone#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Sérogroupe",
"description": "Comment prévenir les infections par sérogroupe ?\nLes vaccins sont-ils efficaces ?\nQuelles mesures d'hygiène sont recommandées ?\nLes voyages augmentent-ils le risque ?\nLes comportements à risque à éviter ?",
"url": "https://questionsmedicales.fr/mesh/D065288?mesh_terms=Deferiprone#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Sérogroupe",
"description": "Quels traitements sont disponibles pour les infections ?\nLes traitements varient-ils selon le sérogroupe ?\nLes vaccins sont-ils disponibles ?\nComment évaluer l'efficacité du traitement ?\nY a-t-il des traitements alternatifs ?",
"url": "https://questionsmedicales.fr/mesh/D065288?mesh_terms=Deferiprone#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Sérogroupe",
"description": "Quelles complications peuvent survenir ?\nLes complications varient-elles selon le sérogroupe ?\nComment prévenir les complications ?\nLes complications peuvent-elles être mortelles ?\nQuels signes indiquent des complications ?",
"url": "https://questionsmedicales.fr/mesh/D065288?mesh_terms=Deferiprone#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Sérogroupe",
"description": "Quels sont les facteurs de risque d'infection ?\nLes antécédents médicaux influencent-ils le risque ?\nLe mode de vie joue-t-il un rôle ?\nLes voyages à l'étranger augmentent-ils le risque ?\nLes conditions environnementales influencent-elles le risque ?",
"url": "https://questionsmedicales.fr/mesh/D065288?mesh_terms=Deferiprone#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier un sérogroupe spécifique ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Par des tests sérologiques qui détectent des anticorps spécifiques."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests ELISA et l'immunofluorescence sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Peut-on diagnostiquer par culture ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la culture de microorganismes peut aider à identifier le sérogroupe."
}
},
{
"@type": "Question",
"name": "Les tests PCR sont-ils utiles ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la PCR peut détecter des séquences spécifiques de l'ADN des microorganismes."
}
},
{
"@type": "Question",
"name": "Quel rôle joue l'historique médical ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'historique aide à orienter les tests et à identifier les sérogroupes possibles."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont associés aux infections par sérogroupe ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes varient, mais incluent fièvre, douleurs et inflammation."
}
},
{
"@type": "Question",
"name": "Les symptômes varient selon le sérogroupe ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, chaque sérogroupe peut provoquer des symptômes spécifiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes communs ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme la fatigue et la fièvre sont souvent communs."
}
},
{
"@type": "Question",
"name": "Les symptômes peuvent-ils être graves ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains sérogroupes peuvent entraîner des complications graves."
}
},
{
"@type": "Question",
"name": "Comment les symptômes évoluent-ils ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent s'aggraver rapidement sans traitement approprié."
}
},
{
"@type": "Question",
"name": "Comment prévenir les infections par sérogroupe ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Par la vaccination, l'hygiène et l'évitement des contacts à risque."
}
},
{
"@type": "Question",
"name": "Les vaccins sont-ils efficaces ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les vaccins peuvent réduire significativement le risque d'infection."
}
},
{
"@type": "Question",
"name": "Quelles mesures d'hygiène sont recommandées ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Se laver les mains régulièrement et éviter les contacts avec des malades."
}
},
{
"@type": "Question",
"name": "Les voyages augmentent-ils le risque ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, voyager dans des zones à risque peut augmenter l'exposition aux sérogroupes."
}
},
{
"@type": "Question",
"name": "Les comportements à risque à éviter ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter les foules et les contacts étroits avec des personnes malades."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour les infections ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antibiotiques ou antiviraux sont souvent utilisés selon le sérogroupe."
}
},
{
"@type": "Question",
"name": "Les traitements varient-ils selon le sérogroupe ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, chaque sérogroupe peut nécessiter un traitement spécifique."
}
},
{
"@type": "Question",
"name": "Les vaccins sont-ils disponibles ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains sérogroupes ont des vaccins pour prévenir les infections."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'efficacité du traitement ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Par le suivi des symptômes et des tests sérologiques après traitement."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements alternatifs ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des traitements complémentaires peuvent être envisagés, mais doivent être validés."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme la septicémie ou des infections localisées peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les complications varient-elles selon le sérogroupe ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, chaque sérogroupe peut entraîner des complications spécifiques."
}
},
{
"@type": "Question",
"name": "Comment prévenir les complications ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un traitement précoce et approprié peut réduire le risque de complications."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles être mortelles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines complications peuvent être graves et potentiellement mortelles."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent des complications ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme une aggravation des symptômes ou une nouvelle fièvre doivent alerter."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque d'infection ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'âge, l'immunodépression et les conditions de vie."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux influencent-ils le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents d'infections augmentent le risque de réinfection."
}
},
{
"@type": "Question",
"name": "Le mode de vie joue-t-il un rôle ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sain peut réduire le risque d'infection."
}
},
{
"@type": "Question",
"name": "Les voyages à l'étranger augmentent-ils le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, voyager dans des zones endémiques expose à des sérogroupes spécifiques."
}
},
{
"@type": "Question",
"name": "Les conditions environnementales influencent-elles le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des conditions comme la pollution ou le surpeuplement peuvent augmenter le risque."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 26/04/2025
Contenu vérifié selon les dernières recommandations médicales
6 publications dans cette catégorie
Affiliations :
Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom.
Meningococcal Reference Unit, Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom.
University of Manchester, Infection, Immunity & Respiratory Medicine, School of Biological Sciences, Stopford Building, Manchester, United Kingdom.
3 publications dans cette catégorie
Affiliations :
State Key Laboratory for Infectious Disease Prevention and Control, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China. pangbo@icdc.cn.
Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, 310003, China. pangbo@icdc.cn.
Publications dans "Sérogroupe" :
3 publications dans cette catégorie
Affiliations :
State Key Laboratory for Infectious Disease Prevention and Control, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China. kanbiao@icdc.cn.
Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, 310003, China. kanbiao@icdc.cn.
Publications dans "Sérogroupe" :
3 publications dans cette catégorie
Affiliations :
Meningitis and Vaccine Preventable Diseases Branch, Centers for Disease Control and Prevention, Atlanta, USA.
Publications dans "Sérogroupe" :
3 publications dans cette catégorie
Publications dans "Sérogroupe" :
3 publications dans cette catégorie
Affiliations :
National Centre for Microbiology, Instituto de Salud Carlos III, Madrid, Spain.
Publications dans "Sérogroupe" :
3 publications dans cette catégorie
Affiliations :
Vaccine Medical Development, Scientific & Clinical Affairs, Pfizer Inc, Collegeville, PA, USA.
Publications dans "Sérogroupe" :
3 publications dans cette catégorie
Affiliations :
Institut Pasteur, Invasive bacterial infections Unit and National Reference Centre for Meningococci and Haemophilus influenzae, Paris, France.
Publications dans "Sérogroupe" :
3 publications dans cette catégorie
Affiliations :
Institute for Hygiene and Microbiology, University of Würzburg, Josef-Schneider-Str. 2, 97080 Würzburg, Germany. Electronic address: vogel_u@ukw.de.
Publications dans "Sérogroupe" :
2 publications dans cette catégorie
Affiliations :
Meningococcal Reference Unit, Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom.
Publications dans "Sérogroupe" :
2 publications dans cette catégorie
Affiliations :
Animal Disease Diagnostic Division, Animal and Plant Quarantine Agency, Gimcheon 39660, Korea.
Publications dans "Sérogroupe" :
2 publications dans cette catégorie
Affiliations :
College of Veterinary Medicine, Chungbuk National University, Cheongju 28644, Korea.
Publications dans "Sérogroupe" :
2 publications dans cette catégorie
Affiliations :
College of Veterinary Medicine, Chungbuk National University, Cheongju 28644, Korea.
Publications dans "Sérogroupe" :
2 publications dans cette catégorie
Affiliations :
State Key Laboratory for Infectious Disease Prevention and Control, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China.
Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, 310003, China.
Publications dans "Sérogroupe" :
2 publications dans cette catégorie
Affiliations :
State Key Laboratory for Infectious Disease Prevention and Control, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China.
Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, 310003, China.
Publications dans "Sérogroupe" :
2 publications dans cette catégorie
Affiliations :
Division of Microbiology, Professor Alborzi Clinical Microbiology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Publications dans "Sérogroupe" :
2 publications dans cette catégorie
Affiliations :
Indian Council of Agricultural Research-National Institute of Veterinary Epidemiology and Disease Informatics, Yelahanka, Bengaluru, Karnataka, India.
Publications dans "Sérogroupe" :
2 publications dans cette catégorie
Affiliations :
Indian Council of Agricultural Research-National Institute of Veterinary Epidemiology and Disease Informatics, Yelahanka, Bengaluru, Karnataka, India.
Publications dans "Sérogroupe" :
2 publications dans cette catégorie
Affiliations :
Department of Veterinary Tropical Diseases, Faculty of Veterinary Science, University of Pretoria, Onderstepoort 0110, South Africa. lokisnyman@gmail.com.
Publications dans "Sérogroupe" :
2 publications dans cette catégorie
Affiliations :
Amsterdam UMC, University of Amsterdam, Netherlands Reference Laboratory for Bacterial Meningitis, The Netherlands.
Publications dans "Sérogroupe" :
The accumulation of iron in dopaminergic neurons can cause oxidative stress and dopaminergic neuron degeneration. Iron chelation therapy may reduce dopaminergic neurodegeneration, but chelators should...
Mitochondrial membrane protein-associated neurodegeneration (MPAN) is a rare and devastating disease caused by pathogenic mutations in C19orf12 gene. MPAN is characterized by pathological iron accumul...
We reported that two sisters from the same family diagnosed with MPAN had dramatically different responses to deferiprone (DFP) treatment. The diagnosis of MPAN were established based on typical clini...
The findings of this study enriched the MPAN gene database and indicated that DFP might ameliorate symptom progression in patients without severe autonomic neuropsychiatric impairment at the early sta...
Non-Tuberculous Mycobacterial Pulmonary Disease (NTM-PD) caused by Mycobacterium abscessus is a frequent complication in patients with cystic fibrosis (CF) that worsens lung function over time. Curren...
Iron overload is a common complication experienced by transfusion-dependent children with hemoglobin disorders. Chelators such as deferasirox (DFX) and deferiprone (DFP) are effective in overcoming th...
PubMed and Cochrane Central were searched from their inception until Dec 21 2021, for randomized clinical trials (RCTs) and observational studies, which assessed the efficacy of DFX compared to DFP in...
A total of 5 studies comprising 607 children were included. The results of our analysis revealed no significant difference between DFX and DFP in MRI T2* at the end of treatment (WMD: -0.92; 95% CI [-...
Our analysis shows no significant difference between the efficacy of DFX and DFP in the management of iron overload in children with inherited blood disorders. Future large-scale clinical trials are r...
The need for preparing new strategies for the design of emergency drug therapies against COVID-19 and similar diseases in the future is rather urgent, considering the high rate of morbidity and especi...
In the absence of YFH1, the yeast ortholog of the human FXN gene, budding yeast Saccharomyces cerevisiae experience similar problems to those of cells with Friedreich's ataxia (FRDA). The comparable p...
Deferiprone (DFP) is an oral iron-chelating agent that is widely used in thalassemia patients with iron overload. This study aimed to investigate the long-term efficacy of DFP monotherapy on serum fer...
The historical insights and background of the discovery, development and clinical use of deferiprone (L1) and the maltol-iron complex, which were discovered over 40 years ago, highlight the difficulti...
Children with sickle cell disease (SCD) who are chronically transfused often, require iron chelation therapy. There are limited data that allow for comparison of the efficacy and safety of the iron ch...
This post hoc analysis of the phase 3b/4, randomized, open-label FIRST (Ferriprox in Patients with IRon Overload in Sickle Cell Disease Trial) study (NCT02041299) included patients 17 years and younge...
Overall, 142 patients were evaluated; mean ages were 10.5 and 11.7 years in the deferiprone and deferoxamine groups, respectively. At 12 months: mean change from baseline in liver iron concentration w...
This post hoc analysis of pediatric patients from FIRST corroborated previous findings in adults that deferiprone is comparable to deferoxamine in reducing iron overload. No new safety concerns were o...
A 56-year-old Thai male, known for allergies to penicillin, sulfa, and lincosamide, presented with hyperferritinemia. Upon initiating deferiprone therapy, the patient experienced recurrent episodes of...